ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (VLZ-MD-21)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01878292
Recruitment Status : Completed
First Posted : June 14, 2013
Last Update Posted : October 7, 2016
Sponsor:
Information provided by (Responsible Party):
Forest Laboratories

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Placebo Drug: Vilazodone Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 529 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Study Start Date : July 2013
Actual Primary Completion Date : March 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Dose-matched placebo tablets, once per day, oral administration
Drug: Placebo
Dose matched placebo tablets, once per day, oral administration.

Experimental: Vilazodone 15 mg
15 mg vilazodone tablets, once per day, oral administration
Drug: Vilazodone
Vilazodone tablets, 15 mg per day, oral administration
Other Name: Viibryd

Experimental: vilazodone 30 mg
30 mg vilazodone tablets, once per day, oral administration
Drug: Vilazodone
Vilazodone tablets, 30 mg once per day, oral administration
Other Name: Viibryd




Primary Outcome Measures :
  1. Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score [ Time Frame: From Baseline to week 8 ]

Secondary Outcome Measures :
  1. Change in Clinical Global Impressions-Severity (CGI-S) Score [ Time Frame: From Baseline to Week 8 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or Female outpatients between 12-17 years of age
  • Primary diagnosis of major depressive disorder (MDD)
  • Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater
  • Clinical Global Impressions-Severity (CGI-S) score of 4 or greater

Exclusion Criteria:

  • Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment.
  • History of suicidal behavior, or requires precaution against suicide
  • Not generally healthy medical condition
  • Seizure disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01878292


  Show 52 Study Locations
Sponsors and Collaborators
Forest Laboratories
Investigators
Study Director: Michelle Aguirre Forest Research Institute, Inc., a Subsidiary of Allergan, PLC.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Forest Laboratories
ClinicalTrials.gov Identifier: NCT01878292     History of Changes
Other Study ID Numbers: VLZ-MD-21
First Posted: June 14, 2013    Key Record Dates
Last Update Posted: October 7, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Vilazodone Hydrochloride
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists